Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal Phase 2/3 study of Rhenium NanoLiposome (RNL) in recurrent glioblastoma

Next Previous
X
Search
Trial Profile

A pivotal Phase 2/3 study of Rhenium NanoLiposome (RNL) in recurrent glioblastoma

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 07 Sep 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rhenium (186Re) obisbemeda (Primary)
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 06 Sep 2022 According to a Plus Therapeutics media release, the Company and the FDA also agreed to hold future meeting(s) to consider the use of external data to augment the control arm in the registrational trial.
    • 06 Sep 2022 According to a Plus Therapeutics media release, there was agreement in type C meeting to use overall survival as a primary endpoint.
    • 13 Jun 2022 According to a Plus Therapeutics media release, the company expect to initiate this trial by the end of 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top